Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
GA Vena, N Cassano, F Iannone - Therapeutics and Clinical Risk …, 2018 - Taylor & Francis
Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated
inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to …
inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to …
[HTML][HTML] Methotrexate: new therapeutic approaches
L Puig - Actas Dermo-Sifiliográficas (English Edition), 2014 - Elsevier
Although the first study on the efficacy of methotrexate in the treatment of psoriasis was
reported in 1958, scientific evidence for this indication has been scant until quite recently …
reported in 1958, scientific evidence for this indication has been scant until quite recently …
Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study
Background Patients with psoriatic disease may be more susceptible to methotrexate
hepatotoxicity than those with rheumatoid arthritis (RA); however, direct evidence supporting …
hepatotoxicity than those with rheumatoid arthritis (RA); however, direct evidence supporting …
Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines
FTM Busger op Vollenbroek, CJM Doggen… - PLoS …, 2018 - journals.plos.org
Background Methotrexate (MTX) is widely used as disease modifying treatment for psoriasis
and psoriatic arthritis (PsA). Rheumatological and dermatological guidelines to prevent MTX …
and psoriatic arthritis (PsA). Rheumatological and dermatological guidelines to prevent MTX …
[HTML][HTML] Metotrexato: novedades terapéuticas
L Puig - Actas Dermo-Sifiliográficas, 2014 - Elsevier
Pese a que el primer estudio sobre la eficacia de metotrexato en el tratamiento de la
psoriasis se remonta a 1958, hasta no hace mucho ha sido escasa la evidencia científica …
psoriasis se remonta a 1958, hasta no hace mucho ha sido escasa la evidencia científica …
Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus
Background After decades of use, methotrexate displays an established safety and efficacy
profile in both in-hospital and outpatient settings. Despite its widespread use, there is …
profile in both in-hospital and outpatient settings. Despite its widespread use, there is …
Patient-ready syringes containing 25 mg/mL methotrexate can be kept at temperature ranging from 4° C to 37° C for up to 12 weeks for use in psoriatic and …
L Chularojanamontri, C Wongpraparut… - Journal of …, 2022 - Taylor & Francis
Background Methotrexate (MTX) is a mainstay drug in the treatment of psoriatic and
rheumatologic conditions. Subcutaneous MTX has become a feasible treatment alternative …
rheumatologic conditions. Subcutaneous MTX has become a feasible treatment alternative …
Frequency of monotherapy versus combination therapy in reported cases of infections occurring in the setting of biologic agents
S Bernardo, L Geraghty, A Freilich, M Pan… - Psoriasis …, 2013 - journals.sagepub.com
The purpose of this work was to determine the frequency with which concomitant
immunosuppressive medications were used in a systemic review of reported cases of …
immunosuppressive medications were used in a systemic review of reported cases of …